218271-92-2

Upstream product

• 593-56-6 N-methoxylamine hydrochloride 
• 218271-90-0 (+)-(4R,5R)-1-(2,2-dimethyl-5-phenylacetyl-[1,3]dioxolan-4-yl)-2-phenylethanone 

Downstream Products

• 218271-99-9 (R)-1-[(4S,5S)-5-((S)-1-Amino-2-phenyl-ethyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-2-phenyl-ethylamine 
• 218271-94-4 (S)-1-[(4S,5S)-5-((S)-1-Amino-2-phenyl-ethyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-2-phenyl-ethylamine 
• 218272-12-9 (3aS,4S,8R,8aS)-4,5,7,8-Tetrabenzyl-2,2-dimethyl-hexahydro-1,3-dioxa-5,7-diaza-azulen-6-one 
• 218272-01-6 (4S,5S,6S,7R)-1,3,4,7-Tetrabenzyl-5,6-dihydroxy-[1,3]diazepan-2-one 
• 218272-00-5 (3aS,4R,8S,8aS)-4,8-Dibenzyl-2,2-dimethyl-hexahydro-1,3-dioxa-5,7-diaza-azulen-6-one 

Relevant academic research and scientific papers

Stereoisomers of cyclic urea HIV-1 protease inhibitors: Synthesis and binding affinities

We have synthesized stereoisomers of cyclic urea HIV-1 protease inhibitors to study the effect of varying configurations on binding affinities. Four different synthetic approaches were used to prepare the desired cyclic urea stereoisomers. The original cy